Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients
MetadataShow full item record
. The aims of this study were to assess hepatitis B surface antigen (HBsAg) seroconversion and to determine its impact on the natural course of the disease in patients with HBeAg-negative chronic hepatitis B (CHB) during lamivudine (LMV) treatment. A total of 183 consecutive patients with HBeAg-negative CHB who were treated with LMV were included in the study. Data were retrospectively collected from outpatient visit charts. The primary endpoint was HBsAg seroconversion to anti-HBs. The secondary endpoint was to determine the development of cirrhosis. Loss of HBsAg was confirmed in 10 patients and seroconversion to anti-HBs in nine patients during LMV treatment or after its discontinuation. HBsAg seroconversion was achieved on-treatment in four patients after a median treatment duration of 30 months and off-treatment in the remaining five patients in a median 61 months after LMV discontinuation. The cumulative probability of HBsAg seroconversion increased from 0.6% at 1 year and 1.9% at 5 years to 21.5% at 10 years of LMV during and after LMV treatment. HBsAg clearance was preceded by undetectable serum hepatitis B virus (HBV) DNA. The majority of the patients responding to treatment had undetectable HBV DNA levels at 24 weeks of treatment. The cumulative probability of LMV resistance increased from 2.2% at 1 year to 37.3% at 5 years. No baseline parameter predicting either HBsAg seroconversion or the emergence of LMV resistance was identified. None of the patients with HBsAg seroconversion experienced virological breakthrough or disease progression during the follow-up period. These results indicate that HBsAg seroclearance can occur in patients with HBeAg-negative CHB under LMV therapy and predicts better clinical outcome.
Idilman R., Cinar K., Seven G., Bozkus Y., Elhan A., Bozdayi M., Yurdaydin C., Bahar K., -Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients-, JOURNAL OF VIRAL HEPATITIS, cilt.19, ss.220-226, 2012
Showing items related by title, author, creator and subject.
New approaches to in vitro diagnosis of hepatitis C infection a reason for post transfusion hepatitis: Diagnostic value of determination of hepatitis C virus core antigen. Yuksel, PELİN; CALISKAN, R; ERGIN, S; ASLAN, M; CELIK, DG; SARIBAS, S; ZIVER, T; YALCINER, A; KOCAZEYBEK, B (2011-12-01)
Distribution of Hepatitis C Virus genotypes in patients with chronic Hepatitis C infection in Eastern Turkey Ozer, Turkan Toka; Berktas, Mustafa; YAMAN, GÖRKEM; Erkoc, Reha (2015-01-01)Viral hepatitis is one of the most important liver diseases in the world. Duration of hepatitis C virus (HCV) infection and response to standard therapy is strongly related to HCV genotypes. Geographical distribution of ...
The seroprevalence of both hepatitis B and hepatitis C at the first-step health organizations and the difference between the urban and rural areas. KALEM, F; YÜKSEKKAYA, Ş; Başaranoğlu, METİN (2016-10-01)